Jeffrey Gordon, MD
Urology · Plymouth Meeting, PANPI 1124068044
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,468 of the $17,012 with a category attached, or 61.5%. 38 manufacturers reported payments, led by Bayer at 27.0% of the total. Among urology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $42.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$5K
- Dendreon Pharmaceuticals LLC$2K
- Johnson & Johnson$1K
- Boston Scientific$1K
- Astellas Pharma US Inc$1K
- Procept Biorobotics Corporation$996
- plus $5K from 32 others
Across 11 payments — averaging $3008.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$33K
What the payments were for
- Consulting fees$4,30825%
- Travel & lodging$1,89111%
- Food & beverage$10,46862%
- Education$3452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 54 | $4,594 |
| Dendreon Pharmaceuticals LLC | 24 | $2,499 |
| Johnson & Johnson | 41 | $1,391 |
| Boston Scientific | 14 | $1,188 |
| Astellas Pharma US Inc | 50 | $1,098 |
| Procept Biorobotics Corporation | 6 | $996 |
| Pfizer | 43 | $695 |
| Sumitomo Pharma America, Inc. | 24 | $491 |
| Progenics Pharmaceuticals, Inc. | 16 | $442 |
| Ferring Pharmaceuticals Inc. | 13 | $437 |
| Myriad Genetic Laboratories, Inc. | 10 | $395 |
| Merck | 11 | $269 |
| Novartis | 10 | $236 |
| Teleflex LLC | 9 | $233 |
| Medtronic | 5 | $195 |
| Sun Pharmaceutical Industries Inc. | 6 | $183 |
| Biosense Webster, Inc. | 3 | $168 |
| AbbVie(2 entities) | 8 | $168 |
| Neotract Inc. | 5 | $165 |
| Janssen Scientific Affairs, LLC | 1 | $145 |
| Tolmar, Inc. | 6 | $138 |
| Myovant Sciences Inc. | 6 | $136 |
| Telix Pharmaceuticals | 6 | $133 |
| AstraZeneca | 6 | $119 |
| Urogen Pharma, Inc. | 6 | $113 |
| Verity Pharmaceuticals Inc. | 4 | $69 |
| Palette Life Sciences, Inc. | 2 | $66 |
| Olympus America Inc. | 2 | $38 |
| Astellas Pharma Global Development | 1 | $34 |
| Dentsply IH AB | 1 | $28 |
| Blue Earth Diagnostics | 1 | $26 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Calyxo, Inc. | 1 | $24 |
| Urovant Sciences Inc | 1 | $24 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $19 |
| Axonics, Inc. | 1 | $14 |
| Immunitybio, Inc. | 1 | $14 |
| Mission Pharmacal Company | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,012 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 295 | $761,482 |
| ErleadaApalutamide | 62 | $703,055 |
| XtandiEnzalutamide | 45 | $520,955 |
| NubeqaDarolutamide | 41 | $418,515 |
| GemtesaVibegron | 142 | $83,334 |
| MyrbetriqMirabegron | 137 | $78,013 |
| Abiraterone Acetate | 42 | $52,830 |
| Tamsulosin Hcl | 746 | $18,465 |
| Finasteride | 330 | $7,251 |
| Silodosin | 45 | $5,729 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 272 | $5,392 |
| Testosterone | 25 | $5,292 |
| Methenamine Hippurate | 49 | $4,876 |
| Trospium Chloride ErTrospium Chloride | 22 | $3,112 |
| Dutasteride | 28 | $1,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $491 | $844,815437 claims |
| Johnson & JohnsonErleada | $1,391 | $703,05562 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $1,098 | $598,968182 claims |
| BayerNubeqa | $4,594 | $418,51541 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $145 | $52,83042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.
Other urology in Plymouth Meeting
- Dean LaganoskyPlymouth Meeting$115K
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Paul SieberLancaster$631K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.